

FOSUN

A GLOBAL
INNOVATION-DRIVEN
CONSUMER GROUP



FOSUN, TOWARDS A BRIGHTER LIFE

Fosun was founded in 1992. After more than 30 years of development, Fosun has become a global innovation-driven consumer group. Adhering to the mission of creating happier lives for families worldwide, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of families worldwide in Health, Happiness and Wealth. In 2007, Fosun International Limited was listed on the main board of the Hong Kong Stock Exchange (stock code: 00656.HK).

MISSION

Creating happier lives for families worldwide

VISION

Rooted in China, Fosun is committed to creating a global happiness ecosystem fulfilling the needs of families worldwide in Health, Happiness, and Wealth

VALUES

Self-improvement, Teamwork, Performance, and
Contribution to Society

173.43 RMB billion

Total revenue in 2025

716.2 RMB billion

Total assets as at
31 December 2025

4.0 RMB billion

Adjusted industrial
operation profit¹ in 2025

54.7%

Proportion of overseas
revenue in 2025

7.8 RMB billion

Investment in technology
and innovation² in 2025

AAA

MSCI ESG rating


* Currency is in RMB and financial data is based on the annual results for the year ended 31 December 2025, unless otherwise specified

¹ It excludes non-cash impairment provisions from subsidiaries

² It includes scientific research investment (expensed and capitalized) but excludes digitalization expenses

ROOTED IN CHINA, DEVELOPING GLOBALLY

Rooted in China, Fosun has been developing globally and has long adhered to the two core growth drivers of "innovation" and "globalization". Fosun is one of the few Chinese companies that is equipped with global operation and investment capabilities, and has accumulated profound technology and innovation capabilities.



OUR STRATEGIES

Fosun adheres to its globalization strategy, continuously innovates to create new momentum, and remains focused on deepening its development in the household consumption industry.

Globalization

Innovation

M20F

S

01

INNOVATION-DRIVEN

A global innovation system that delivers innovative achievements with global competitiveness.

R&D Innovation

HANSIZHUANG

The phase III clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its primary endpoint of Event-Free Survival (EFS), potentially ushering in a "chemotherapy-free" era in perioperative cancer treatment.

HLX43

As a potential broad-spectrum anti-tumor PD-L1 antibody drug conjugate (ADC), HLX43 is rapidly advancing as a monotherapy, demonstrating significant advantages of "high efficacy and low toxicity" across multiple therapeutic areas.

FUMAINING

FUMAINING (lvoxmetinib tablets), an innovative small molecule drug independently developed by Fosun Pharma, received approval for two indications in Chinese mainland, filling the gap in the treatment of rare tumors in China.

FUTUONING

FUTUONING (fovinacilicib citrate capsules), a CDK4/6 inhibitor, has been launched for two indications, offering a brand-new treatment option for breast cancer patients.

Fosun's second CAR-T product

The marketing application of Fosun's second CAR-T product, brexucabtagene autoleucel injection, has been accepted by the National Medical Products Administration (NMPA).

Domestically produced Da Vinci Xi Surgical System

The Da Vinci surgical system has been successfully localized and commercialized domestically.

Ion Robotic Bronchoscopy

The Ion Robotic Bronchoscopy (the Ion System) has been successfully approved for launch and commercialization in Chinese mainland

7.8 Billion RMB


Investment in technology and innovation¹ in 2025

20+

Global technology innovation centers

FOSUN

Technology Innovation Centers in Various Fields



- Fosun Pharma Global R&D Center (national level)
- Fosun Pharma North America R&D Headquarters
- Fosun Pharma Academician Expert Workstation
- Henlius Global Innovation Center
- Fosun Kairos R&D Center
- Jiangsu Wanbang Recombinant Protein Drug Engineering Center
- Jiangsu Wanbang Engineering Research Center for Diabetic Drugs
- Chongqing Yao Pharma National-Local Joint Research Center for Lyophilized Preparations
- Chongqing Pharmaceutical Research Institute
- Liaoning AVANC Pharma Professional Technology Innovation Center for Tumor and Perioperative Drugs
- Foshan Fosun Chan cheng Hospital Tumor Precision Key Laboratory
- Intuitive Fosun Headquarters Industrial Base
- Sisram x Shinrong Medical Aesthetics Innovation R&D Center
- Hainan Mining Technology Center
- Hainan Mining Academician Expert Workstation
- Wansheng Technology Center (national level)
- Easun Technology Global R&D Center
- Sichuan Shede Spirits Intelligent Brewing Engineering Technology Center
- Tianjin Seagull High-Precision Mechanical Watch Enterprise Key Laboratory
- Fosun Jinmei Cosmetics Global Innovation Center (CNAS certified)
- Yuyuan Foods & Dining Group Innovation Center
- Fosun Wine & Spirits Global Innovation Center
- Yuyuan Jewelry Creative House
- Lanvin Group Fabric Innovation Center

¹ It includes scientific research investment (expensed and capitalized) but excludes digitalization expenses

ALL IN ON AI APPLICATIONS TO ACCELERATE INNOVATION

Fosun's AI strategy aims to lead the industry in AI adoption, evolving from "business + AI" to "AI + business".



AI Applications

PharmAID decision intelligence platform

Fosun Pharma has built the industry's first decision intelligence platform, improving the efficiency of drug R&D and intelligent extraction of industry insights by approximately 50%

HAI Club

Henlius has developed an AI-powered, all-in-one early-stage antibody drug R&D platform

AI G.O


FTG's AI G.O intelligent system has been successfully deployed at Atlantis Sanya and multiple Club Med resorts in China

AI applications at Fosun Insurance Portugal (Fidelidade)

Fosun Insurance Portugal's digital user base reached nearly 22% of Portugal's population, with large AI models beginning to create business value across segments

PROFOUND GLOBAL OPERATIONS

The globalization journey of Fosun began with the listing of Fosun International in Hong Kong. After 18 years since its listing, Fosun has established a business presence in more than 40 countries and regions around the world. Since 2022, the model of "global organization + local operations" has become more mature. Operations are at the core of Fosun's future globalization.



PROFOUND GLOBAL OPERATIONS

Fosun's globalization has entered the 3.0 era of "Combining Global Resources with China's Capabilities", building global operating capabilities that integrates "global footprint, global R&D, global supply chain, and global commercialization" in core businesses.

94.86 Billion RMB
Overseas revenue in 2025

54.7%
Overseas revenue
proportion in 2025

Growth driven by both domestic and overseas insurance companies

Fidelidade

Continued to consolidate its leading position in the Portuguese market, with a market share of 28.1%. Meanwhile, its international business maintained rapid growth, contributing more than 30% of the company's total gross written premiums, with Latin America accounting for over 60%.

Peak Reinsurance

Obtained a license to establish a reinsurance branch in Gujarat International Finance Tec-City (GIFT City) in India, maintaining strong momentum in emerging market.

Pramerica Fosun Life Insurance

Premium income for the year reached RMB13.28 billion, up 41.6% year-on-year, while net profit surged 492% to RMB650 million.

Fosun United Health Insurance

Recorded insurance income of RMB7.84 billion in 2025, up 50.1% year-on-year, and achieved net profit of RMB139 million, marking its fifth consecutive year of profitability.

Overseas launch of innovative pharmaceutical products

YP05002

Fosun Pharma's global licensing deal of the GLP-1 target YP05002 garnered an upfront payment of USD150 million and potential total payments of USD2.085 billion.

Henlius

Henlius has 10 products approved for marketing in nearly 60 countries and regions worldwide, benefiting over 1 million patients globally.

HANQUYOU

HANQUYOU has been approved for marketing in over 50 countries and regions and has been included in reimbursement systems in China, the U.K., France, Germany and other countries. It recorded global sales revenue of RMB2.9645 billion in 2025, up 5.5% year-on-year.

HANSIZHUANG

HANSIZHUANG has been approved for marketing in more than 40 countries and regions and recorded global sales revenue of RMB1.4926 billion in 2025, up 13.7% year-on-year.

Deepening global operations through global expansion

Club Med

Club Med, which operates 67 resorts worldwide, achieved another record-high performance in 2025, with business volume reaching RMB17.97 billion, up 2.1% year-on-year.

Hainan Mining

Hainan Mining has established a global resource network covering various strategic mineral resources. Its Bougouni lithium mine in Mali produced 45,000 tons of lithium concentrate in 2025. Hainan Mining also completed the acquisition of the Oman oilfield project.

DEVELOP HIGH-QUALITY PROJECTS WITH ASSET-LIGHT OPERATIONS

Building on its profound industrial operation capabilities accumulated over 30 years, along with its advantages in innovation and globalization, Fosun has joined hands with various partners to deploy advantageous industries and develop high-quality projects.



Fosun Pharma

Fosun Pharma together with the Shenzhen Guidance Fund and other investors established a RMB5.0 billion biopharmaceutical industry fund, managed by Fosun Health Capital.

Taicang Alps Resort Phase II

Funded by the Taicang Municipal Government platform with a total investment of approximately RMB5 billion and managed by FTG.

Hi•Chongqing

FTG signed a cooperation agreement with the Chongqing Municipal Government platform to take on the renovation and operational management of the Chongqing China Mall Project under an asset-light model, creating a large-scale indoor themed tourism and entertainment park.

Asset-light operation in Jinsha Bay, Shenzhen

FTG signed an asset-light operation agreement for the Jinsha Bay project in Shenzhen, marking the launch of the first Club Med in the Greater Bay Area.

Club Med

85% of Club Med resorts have adopted a leasing and management model.

TALENT, THE MOST VALUABLE ASSET OF FOSUN

A robust team of talent determines the scalability of the company's future development.

ELITE MANAGEMENT TEAM

- 160+ global partners
- 470+ industry partners
- 450+ functional line partners
- 40+ innovation partners

GLOCAL

- 40+ overseas global partners from countries including Portugal, France, Germany, the United Kingdom, Japan, India, and the United States

TALENT DEVELOPMENT STRATEGY

- Attract talent with development, appraise talent based on performance, train talent through work, and unite talent with career opportunities



OUR BUSINESSES

Fosun continues to focus on its four major business segments: Health, Happiness, Wealth, and Intelligent Manufacturing, providing high-quality products and services to families worldwide.

Its four core subsidiaries – Fosun Pharma, Yuyuan, Fosun Insurance Portugal (Fidelidade), and FTG – generated a total revenue of RMB128.2 billion in 2025, accounting for 74% of the Group's total revenue.



HEALTH



HAPPINESS



WEALTH



INTELLIGENT
MANUFACTURING

HEALTH SEGMENT

BIOPHARMACEUTICALS

Through an open and globally integrated pharmaceutical R&D system with independent R&D, co-development, license-in and industrial investment, Fosun's Health segment focuses on core therapeutic areas, including oncology (solid tumors and hematologic malignancies) as well as immunology and inflammation. Fosun places special emphasis on strengthening core technology platforms for antibodies and antibody drug conjugates (ADC), cell therapies and small molecules, while deploying cutting-edge therapeutic modalities such as radiopharmaceuticals, RNA therapeutics, gene therapies and AI-powered drug R&D through industry funds.

FOSUN PHARMA
复星医药

 **Henlius**

FOSUN KAIROS
复星凯瑞

FOSUN ADGENVAX
复星安特金

 **GLAND**

DEVICES & DIAGNOSTICS

Medical aesthetics, respiratory health, professional medical devices, and medical diagnostics.

FOSUN MEDTECH
复星医疗器械

FOSUN DIAGNOSTICS
复星诊断

 **sisram**
medical

 **博毅雅**

FOSUN INSIGHTEC
复星医视特

INTUITIVE FOSUN
直观复星

HEALTHCARE SERVICES

Focusing on high-quality medical and professional services, the offerings include combined insurance, health consumption, and wellness solutions, designed to create a comprehensive closed-loop solution.

FOSUN HEALTH
复星健康

 **佛山复星禅诚医院**
FOSHAN FOSUN CHANCHENG HOSPITAL

 **JOYFUL WAY**
卓尔荟

LUZ SAÚDE

 **健嘉医疗**
SANJA HEALTHCARE

FOSUNCARE
复星康养

Continue to drive global industrial innovation to create a medical-grade, one-stop, all-scenario health ecosystem

FOSUN PHARMA

复星医药

A GLOBAL LEADING INTEGRATOR OF PHARMACEUTICAL AND HEALTHCARE INNOVATION

41.662 RMB billion

Operating revenue in 2025

9.893 RMB billion

Revenue from innovative drugs

5.913 RMB billion

R&D investment in 2025

Founded in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a global innovation-driven pharmaceutical and healthcare industry group with deep roots in China. Fosun Pharma directly operates businesses including pharmaceuticals, medical devices, medical diagnosis, and healthcare services. As a shareholder of Sinopharm Co., Ltd., Fosun Pharma expands its presence in the pharmaceutical distribution and retail business.

INNOVATIVE R&D PLATFORMS

Global R&D Center

Small molecule innovative drug platform
Collaboratively developed compounds
Radiopharmaceutical technology platform
Autoimmune disease field

Henlius

Antibody, ADC, and other large molecule technology platforms

Fosun Kairos

Cell therapy technology platform

Pharmaceuticals

Innovative drugs
Mature products and manufacturing
Vaccines

Medical Devices and Medical Diagnostics

Medical devices
Medical diagnostics

Healthcare Services

Online medical service platform
Offline medical institutions (including rehabilitation medical institutions)

HAPPINESS SEGMENT

FAMILY CONSUMPTION

Leverage fashion and diverse experiences to drive family consumption.

豫园股份
YUYUAN Inc.

LANVIN GROUP
复朗集团

豫园商城
YUYUAN GARDEN MALLS

老庙

DJULA
PARIS

琥珀

上海老饭店

上海老饭店
SUZHOU NOODLES

松鹤楼
SUZHOU NOODLES

SEA-GULL
海鸥

SHANGHAI
SINCE 1950

舍得酒业
SHEDU SPIRITS

夜郎古酒

壹佰零壹
YIBAIYONGYI

AHAVA

LANVIN

sergio rossi

Wolford

ST. JOHN

Wolverhampton
Wanderers FC

WOLVES

TOM TAILOR

StHubert
圣格活

Silver Cross

Lowlink
百合佳缘

CHSTR
杭州台铁路

WOLFRAM
复星珠宝

CULTURAL TOURISM BUSINESS

Provide families worldwide with "vacation-like lifestyle" and "lifestyle-based vacation". By aligning global resources, Fosun aims to create "super tourism destinations" to amplify the "tourism+" effect.

FOSUN Holiday
复星旅文

Club Med
地中海俱乐部

ATLANTIS
SANYA
三亚·亚特兰蒂斯

太台阿尔卑斯国际度假区
TAICANG ALPS RESORT

丽江悦中海国际度假区
LIJIANG CLUB MED RESORT

重庆
CHONGQING
SPHERE

ULTRAMED
HAIKOU
海南超级地中海

Center on family consumption and cultural tourism to build a global, industry-wide happiness ecosystem

豫园股份
YUYUAN Inc.



A WORLD-CLASS HAPPINESS
CONSUMER GROUP

36.4 ^{RMB}
billion

Operating revenue in 2025

72%

Revenue proportion from
consumer industries

3,963

Jewelry and fashion stores

Over 40 million

Customer traffic in Yuyuan
Malls in 2025



Yuyuan, with a portfolio of 19 China time-honored brands, 8 intangible cultural heritage projects at the municipal level or higher, and a range of leading brands, leads the trend of Chinese cultural revival through oriental lifestyle aesthetics. As the first batch of Chinese commercial stocks, Yuyuan leads the trend of Chinese cultural revival and develops a world-class happiness consumer group rooted in China.



Jewelry and Fashion Cultural Food and Dining

Chinese Watches Beauty and Health Complex Functional Real Estate

2026

上海豫园灯会

豫园·BFC·外滩 01/26 · 03/03

FOSUN *Holiday*
复星旅文

A WORLD-LEADING LEISURE-FOCUSED
INTEGRATED TOURISM GROUP



Fosun Tourism Group (also known as "FTG" and "Fosun Holiday"), is a world-leading leisure-focused integrated tourism group. Embracing the mission of "Better Holiday, Better Life", FTG endeavors to pioneer holiday lifestyle and create a world-leading family leisure and tourism ecosystem.

19.0 RMB billion

Business volume in 2025

Nearly **70**

Hotels and resorts

40+

Countries and regions with sales and operations

8.60 million

Guests served annually

Super Resort

Center on Club Med, it includes 67 globally operated all-inclusive Club Med resorts such as Club Med Joyview and Club Med Urban Oasis.



Super Resort Complex

It includes ULTRAMED resort complexes such as Atlantis Sanya, Taicang Alps Resort and Lijiang Club Med Resort.



Super Culture and Tourism Mall

Represented by HiSphere Chongqing, it is reshaping urban retail through content and entertainment, revitalizing existing commercial space



WEALTH SEGMENT

Focus on the two major fields of insurance and asset management to build the Fosun Wealth ecosystem

INSURANCE

Establish a global presence and adhere to innovative development and insurance ecosystem development.



INVESTMENT MANAGEMENT

Leverage industrial investment + financial investment as twin drivers to empower Health, Happiness, Wealth, and Intelligent Manufacturing in every stage of life.



HIVE ASSET MANAGEMENT

Establish a global urban hive benchmark



FIDELIDADE

SEGUROS DESDE 1808



Fidelidade is the market leader in Portugal, both in life and non-life segments. Guided by the values of "experience, innovation, overcoming and proximity", Fidelidade conducts its activity with a "Customer Centric Approach" strategy.

A LEADING GLOBAL INSURANCE COMPANY IN PORTUGAL

LOCAL LEADERSHIP

Continued to consolidate its leading position in the Portuguese market, with a market share of 28.1%

INTERNATIONAL DEVELOPMENT

International business contributed more than 30% of the company's total gross written premiums, with Latin America accounting for over 60%.

INNOVATIVE AI APPLICATIONS

Digital user base reached nearly 22% of Portugal's population, with large AI models beginning to create business value across segments

A S&P rating

International rating agency S&P initiated coverage

INTELLIGENT MANUFACTURING SEGMENT

With strategic resources, functional new materials, and intelligent manufacturing as the core, Fosun empowers high-end, intelligent and green transformation of the industry



Green & Low-Carbon Resources

Leverage iron ore, oil and gas, and new energy to establish a foothold in strategic resources and energy

- Improved quality and efficiency in the iron ore business: in 2025, crude ore output reached 5.28 million tons, while finished iron ore output (lump ore + iron concentrate) totaled 2.19 million tons.
- Oil and gas production reached a record high: acquisitions doubled attributable crude oil output, and peak daily production at the Bajiaochang gas field reached a record high of over 4.7 million cubic meters.
- A fully integrated new energy value chain continued to take shape: the first batch of lithium hydroxide products was sold in 2025. The first 30,000 tons of lithium concentrate produced from the Bougouni lithium mine in Mali arrived at Hainan's Yangpu Port.



Functional New Materials

Achieve breakthroughs in advanced materials core technology to support the upgrading of high-end manufacturing

- Global expansion achieved a major breakthrough: construction of the Thailand manufacturing base commenced in 2025.
- Core products sustained strong growth, while new products expansion continued: sales of polymer functional additives and coating additives grew steadily, alongside active investment in new product R&D and industrialization.
- M&A integration deepened, and the BD mechanism proved effective: the integration of Guangzhou Shine Polymer strengthened synergies across product offerings, core technologies, and market channels.



Industrial Automation and Digitalization

A leader in intelligent manufacturing systems, facilitating the intelligent transformation of the manufacturing industry

- Globalization efforts continued to break new ground, with benchmark projects delivered: secured major turnkey projects from CEER, an electric vehicle brand in Saudi Arabia, and Lucid and successfully delivered BMW's Gen6 battery coating solution.
- R&D remained a strategic priority, earning recognition from major national programs: received two national major science and technology projects from the Ministry of Industry and Information Technology, was named a national specialized, sophisticated, distinctive, and innovative "Little Giant" enterprise, and secured a National Natural Science Foundation of China (NSFC) project.
- Improved operational efficiency through AI adoption: AI platform selection and intelligent agent validation were completed, with early efficiency improvements beginning to materialize.

REMARKABLE ESG ACHIEVEMENTS

For a brighter life

AAA MSCI ESG
Rating upgraded

AA- HSI ESG

73 S&P Global Corporate Sustainability Assessment (CSA) score

4.2 FTSE Russell ESG score

Included in S&P Global's "Sustainability Yearbook 2026"

Continuously recognized as a constituent of the FTSE4Good Index

CARBON NEUTRALITY STRATEGY

- Strive to peak carbon emissions by 2028 and achieve carbon neutrality by 2050
- EHS management framework
- Climate risk response

FOSUN FOR GOOD

- Rural Doctors Program
- Assist WHO in building a malaria-free world

CORPORATE GOVERNANCE

- Continue to optimize and evolve corporate risk management
- Improve ESG governance structure
- Proactive two-way communication
- Strengthen information disclosure based on GRI standards and Hong Kong Stock Exchange's New Climate Requirements

E S G

FOSUN FOR GOOD

Established in 2012, Fosun Foundation serves as the principal philanthropic entity of Fosun and is recognized as a "5A Social Organization" in China. Upholding Fosun's corporate value of "Contribution to Society", the foundation carries out philanthropic initiatives across global emergency relief, rural revitalization, healthcare support, youth entrepreneurship, education, and culture & art, with its initiatives reaching numerous countries and regions worldwide.

Regarding rural revitalization, the Rural Doctors Program trains and retains qualified rural doctors, and enhances the capacity and accessibility of primary healthcare services to reduce poverty and the risk of returning to poverty caused by illness, supporting the "Healthy China 2030" vision. Regarding youth entrepreneurship and education, the Protechtig Open Innovation Program empowers global youth in the AI+ era to realize their entrepreneurial dreams. The Infinite Visionaries Award encourages young people to advance the United Nations Sustainable Development Goals (SDGs) through innovative public welfare projects, empowering Chinese youth to bring their philanthropic efforts onto the global stage. In response to sudden global disasters, Fosun Foundation embodies the humanitarian spirit by swiftly providing relief support and care to affected areas.





RURAL DOCTORS PROGRAM

Rural doctors are the "gatekeepers" of grassroots health. In late 2017, under the guidance of the National Health Commission Poverty Relief Office, Fosun Foundation, together with China Population Welfare Foundation and other units, initiated the Health by Heart - Rural Doctors Program ("Rural Doctors Program"), which focuses on safeguarding, empowering and incentivizing rural doctors, implementing a comprehensive support plan centered around the 5 "One Action" to protect grassroots health.

78

Counties covered in 16 provinces, cities and autonomous regions

25,000

Rural doctors served

3 million

Rural families benefited

16.34 million

Rural residents benefited

FIGHT AGAINST MALARIA WORLDWIDE

Second-generation artesunate for injection, Argesun®

Argesun®, the second-generation artesunate for injection has become the first artesunate injectable presented with a single solvent system that received World Health Organization prequalification (WHO PQ), greatly enhancing convenience for clinical use.

440 million

As at the end of 2025, Fosun Pharma had supplied a cumulative total of over 440 million doses of artesunate for injection globally

88+ million

Artesunate for injection has saved the lives of more than 88 million patients with severe malaria



FOSUN

FOSUN FOUNDATION 复星艺术中心



The first 3A social organization among Shanghai contemporary art institutions



The first governing unit of Shanghai Art Museum Association



Shanghai Municipal Administration of Culture and Tourism's "Civilization and Integrity, Art Appreciation" co-construction unit, Shanghai Public Welfare Base, Donghua University Aesthetic Education Practice Base

40+ art exhibitions

Committed to presenting international and Chinese contemporary art exhibitions and special exhibitions with rich content, including "Tadao Ando: Endeavors", "Yayoi Kusama: All About Love Speaks Forever", "Liu Jianhua: Metaphysical Objects", etc.

2 million+ visitors

Fosun Foundation (Shanghai) aims to promote contemporary art and is committed to binding Chinese and international art and culture, and promote public awareness, understanding and engagement in global contemporary art. Fosun Foundation (Shanghai) continues to support local Chinese artists, providing a broad display platform for outstanding Chinese contemporary art works. Fosun Foundation (Shanghai) is located in the Bund Finance Center. Fosun Foundation (Chengdu) was opened in June 2022. Fosun Foundation (Shanghai) participates in, witnesses and leads the development of contemporary art and culture. As an art consultant, Fosun Foundation (Shanghai) has long showcased its collection of Chinese art works in global landmark buildings such as 28 Liberty in New York to promote global cultural and artistic exchanges.

600+ public education campaigns

Insist on organizing high-quality public education campaigns to help the public understand art and promote active participation in art-related events

50,000+ participants in public education campaigns

500+ Fosun Foundation (Shanghai) Night and Aesthetic Journey

Organize diversified and comprehensive cross-brand activities to promote public awareness and public engagement in the latest contemporary art trends

FOSUN

TOWARDS A BRIGHTER LIFE



WeChat



Weibo



WeChat Chan nels



Douyin

HONG KONG

Room 808, ICBC Tower, 3 Garden Road,
Central, Hong Kong
Tel: +852 2509 3228
Fax: +852 2509 9028

SHANGHAI

The Bund Finance Center, No. 600 Zhongshan
East 2nd Road, Huangpu District, Shanghai
Tel: +86 21 2315 6666
Fax: +86 21 6130 3288
Postal Code: 200010